A recent FDA Warning Letter (10 March 2026) to Simtra BioPharma Solutions highlights a pattern the industry keeps seeing in sterile manufacturing. Not one failure but a chain of small ones. The result: FDA concluded the site could not reliably assure sterility. The lesson is simple. When these drift apart, regulators eventually connect the dots….
Addressing the recent FDA Form 483 issued to a firm has outlined compliance Concern: A Call for Data Integrity and Accountability – A recent FDA Form 483 issued to a firm has outlined several critical observations that highlight significant deficiencies in compliance and quality management systems where DATA INTEGRITY, RESPONSIBILITY, and ACCOUTABILITY are apparently lacking….
This time we focus on a drug manufacturing facility in South Korea, issued a Warning Letter on June 12, 2024 Inadequate Validation of Manufacturing Processes The facility failed to adequately validate manufacturing processes for their over-the-counter (OTC) drug product. This includes insufficient data to demonstrate process validation and equipment qualification. Corrective Actions –…
A Waring Letter (#659142) issued to a US based compounding facility for several serious cGMP violations, including: Several other violations were listed for non-HEPA filtered air, lack of validation of aseptic processes, inadequate cleaning and disinfection, issues with facility design, inadequate environmental monitoring, lack of final product testing and an inadequate stability program. …
A prominent manufacturer of over-the-counter drug products, was recently issued a detailed FDA warning letter (#663478) for a number of cGMP violations, including: Insufficient Verification of Component Identity The company failed to conduct necessary tests to confirm the identity of each component used in drug products, including high-risk components like glycerin and propylene glycol, which…
